Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of low-dose decitabine alone or with valproic acid and/or all-trans retinoic acid in older patients with acute myeloid leukemia unfit for induction chemotherapy
2009-009916-33Phase 2Completed
- Sponsor
- University Hospital Freiburg
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of decitabine, valproic acid and tretinoin in acute myeloid leukemia (AML) (4 arms), sponsored by University Hospital Freiburg. Primary endpoint: Objective best response rate. Started Oct 2010; status: completed.
02
Drugs
decitabinevalproic acidtretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-009916-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009916-33.